Literature DB >> 12072493

Characterization of low- and very-low-density hepatitis C virus RNA-containing particles.

P André1, F Komurian-Pradel, S Deforges, M Perret, J L Berland, M Sodoyer, S Pol, C Bréchot, G Paranhos-Baccalà, V Lotteau.   

Abstract

The presence of hepatitis C virus (HCV) RNA-containing particles in the low-density fractions of plasma has been associated with high infectivity. However, the nature of circulating HCV particles and their association with immunoglobulins or lipoproteins as well as the characterization of cell entry have all been subject to conflicting reports. For a better analysis of HCV RNA-containing particles, we quantified HCV RNA in the low-density fractions of plasma corresponding to the very-low-density lipoprotein (VLDL), intermediate-density lipoprotein, and low-density lipoprotein (LDL) fractions from untreated chronically HCV-infected patients. HCV RNA was always found in at least one of these fractions and represented 8 to 95% of the total plasma HCV RNA. Surprisingly, immunoglobulins G and M were also found in the low-density fractions and could be used to purify the HCV RNA-containing particles (lipo-viro-particles [LVP]). Purified LVP were rich in triglycerides; contained at least apolipoprotein B, HCV RNA, and core protein; and appeared as large spherical particles with a diameter of more than 100 nm and with internal structures. Delipidation of these particles resulted in capsid-like structures recognized by anti-HCV core protein antibody. Purified LVP efficiently bind and enter hepatocyte cell lines, while serum or whole-density fractions do not. Binding of these particles was competed out by VLDL and LDL from noninfected donors and was blocked by anti-apolipoprotein B and E antibodies, whereas upregulation of the LDL receptor increased their internalization. These results suggest that the infectivity of LVP is mediated by endogenous proteins rather than by viral components providing a mechanism of escape from the humoral immune response.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12072493      PMCID: PMC136313          DOI: 10.1128/jvi.76.14.6919-6928.2002

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  41 in total

1.  Hepatitis C virus core particle detected by immunoelectron microscopy and optical rotation technique.

Authors:  S Ishida; M Kaito; M Kohara; K Tsukiyama-Kohora; N Fujita; J Ikoma; Y Adachi; S Watanabe
Journal:  Hepatol Res       Date:  2001-07       Impact factor: 4.288

2.  Density heterogeneities of hepatitis C virus in human sera due to the binding of beta-lipoproteins and immunoglobulins.

Authors:  R Thomssen; S Bonk; A Thiele
Journal:  Med Microbiol Immunol       Date:  1993-12       Impact factor: 3.402

3.  Cell fusion activity of hepatitis C virus envelope proteins.

Authors:  S Takikawa; K Ishii; H Aizaki; T Suzuki; H Asakura; Y Matsuura; T Miyamura
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

4.  Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein.

Authors:  P Farci; A Shimoda; D Wong; T Cabezon; D De Gioannis; A Strazzera; Y Shimizu; M Shapiro; H J Alter; R H Purcell
Journal:  Proc Natl Acad Sci U S A       Date:  1996-12-24       Impact factor: 11.205

5.  Construction and characterization of chimeric hepatitis C virus E2 glycoproteins: analysis of regions critical for glycoprotein aggregation and CD81 binding.

Authors:  Arvind H Patel; Jonny Wood; Francois Penin; Jean Dubuisson; J A McKeating
Journal:  J Gen Virol       Date:  2000-12       Impact factor: 3.891

6.  Examination of the buoyant density of hepatitis C virus by the polymerase chain reaction.

Authors:  R J Carrick; G G Schlauder; D A Peterson; I K Mushahwar
Journal:  J Virol Methods       Date:  1992-09       Impact factor: 2.014

7.  Equilibrium centrifugation studies of hepatitis C virus: evidence for circulating immune complexes.

Authors:  M Hijikata; Y K Shimizu; H Kato; A Iwamoto; J W Shih; H J Alter; R H Purcell; H Yoshikura
Journal:  J Virol       Date:  1993-04       Impact factor: 5.103

8.  Purification of the low density lipoprotein receptor, an acidic glycoprotein of 164,000 molecular weight.

Authors:  W J Schneider; U Beisiegel; J L Goldstein; M S Brown
Journal:  J Biol Chem       Date:  1982-03-10       Impact factor: 5.157

9.  The receptor-binding domain of human apolipoprotein E. Monoclonal antibody inhibition of binding.

Authors:  K H Weisgraber; T L Innerarity; K J Harder; R W Mahley; R W Milne; Y L Marcel; J T Sparrow
Journal:  J Biol Chem       Date:  1983-10-25       Impact factor: 5.157

10.  Extraordinarily low density of hepatitis C virus estimated by sucrose density gradient centrifugation and the polymerase chain reaction.

Authors:  H Miyamoto; H Okamoto; K Sato; T Tanaka; S Mishiro
Journal:  J Gen Virol       Date:  1992-03       Impact factor: 3.891

View more
  246 in total

Review 1.  Hepatitis C virus: assembly and release of virus particles.

Authors:  Daniel M Jones; John McLauchlan
Journal:  J Biol Chem       Date:  2010-05-10       Impact factor: 5.157

2.  Dengue virus-induced autophagy regulates lipid metabolism.

Authors:  Nicholas S Heaton; Glenn Randall
Journal:  Cell Host Microbe       Date:  2010-11-18       Impact factor: 21.023

3.  Increased hepatic expression of miRNA-122 in patients infected with HCV genotype 3.

Authors:  Ketti G Oliveira; Fernanda M Malta; Ana C S S Nastri; Azzo Widman; Paola L Faria; Rúbia A F Santana; Venâncio A F Alves; Flair J Carrilho; João R R Pinho
Journal:  Med Microbiol Immunol       Date:  2015-08-14       Impact factor: 3.402

Review 4.  Molecular biology of hepatitis C virus.

Authors:  Tetsuro Suzuki; Hideki Aizaki; Kyoko Murakami; Ikuo Shoji; Takaji Wakita
Journal:  J Gastroenterol       Date:  2007-06-29       Impact factor: 7.527

5.  Protein kinase D negatively regulates hepatitis C virus secretion through phosphorylation of oxysterol-binding protein and ceramide transfer protein.

Authors:  Yutaka Amako; Gulam H Syed; Aleem Siddiqui
Journal:  J Biol Chem       Date:  2011-02-01       Impact factor: 5.157

6.  Cooperativity in virus neutralization by human monoclonal antibodies to two adjacent regions located at the amino terminus of hepatitis C virus E2 glycoprotein.

Authors:  Zhenyong Keck; Wenyan Wang; Yong Wang; Patrick Lau; Thomas H R Carlsen; Jannick Prentoe; Jinming Xia; Arvind H Patel; Jens Bukh; Steven K H Foung
Journal:  J Virol       Date:  2012-10-24       Impact factor: 5.103

7.  Monoclonal antibody AP33 defines a broadly neutralizing epitope on the hepatitis C virus E2 envelope glycoprotein.

Authors:  Ania Owsianka; Alexander W Tarr; Vicky S Juttla; Dimitri Lavillette; Birke Bartosch; François-Loïc Cosset; Jonathan K Ball; Arvind H Patel
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

8.  Apolipoprotein c1 association with hepatitis C virus.

Authors:  Jean-Christophe Meunier; Rodney S Russell; Ronald E Engle; Kristina N Faulk; Robert H Purcell; Suzanne U Emerson
Journal:  J Virol       Date:  2008-07-30       Impact factor: 5.103

9.  TM6SF2 Promotes Lipidation and Secretion of Hepatitis C Virus in Infected Hepatocytes.

Authors:  Audrey Boyer; Seung Bum Park; Ynto S de Boer; Qisheng Li; T Jake Liang
Journal:  Gastroenterology       Date:  2018-08-23       Impact factor: 22.682

10.  Very-low-density lipoprotein (VLDL)-producing and hepatitis C virus-replicating HepG2 cells secrete no more lipoviroparticles than VLDL-deficient Huh7.5 cells.

Authors:  Baptiste Jammart; Maud Michelet; Eve-Isabelle Pécheur; Romain Parent; Birke Bartosch; Fabien Zoulim; David Durantel
Journal:  J Virol       Date:  2013-02-20       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.